Schoenberg Mark 4

What Happened
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 10,000 shares on 2026-06-22 in an open-market transaction. The weighted average sale price was $35.01 per share (range $35.00–$35.08), for aggregate proceeds of approximately $350,100. This was a sale (S) and not a purchase—sales are often routine and may not indicate a change in sentiment.

Key Details

• Transaction date: 2026-06-22; Form filed: 2026-06-24 (filed within typical two-business-day window).
• Shares sold: 10,000; weighted average price: $35.01; price range: $35.00–$35.08.
• Total reported proceeds: ~$350,100.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote F1: Trade executed pursuant to a Rule 10b5-1(c) trading plan adopted 2025-08-15 (pre-scheduled plan).
• Footnote F2: Price is weighted average; seller can provide per-trade breakdown on request.

Context
Sales made under an established 10b5-1 plan are typically pre-planned and reduce the likelihood that the trade reflects the insider’s immediate view of company prospects. For retail investors, purchases usually carry more informational weight than routine sales; this transaction should be viewed as a planned disposition unless other disclosures suggest otherwise.